Hungary Country Profile 2024 | Cromos Pharma
Exploring Clinical Trial Opportunities: Hungary’s 2024 Country Profile Hungary is recognized for its advanced regulatory framework and state-of-the-art healthcare infrastructure, attracting pharmaceutical companies and clinical research organizations (CROs) to carry out their clinical trials there. The country’s clinical trial approval process is efficient and streamlined, in line with European Union standards, which substantially shortens the time needed to initiate new trials. As a Read more
World Kidney Day 2024 | Cromos Pharma
World Kidney Day 2024 World Kidney Day is an  annual global event on the second Thursday of March, focusing on raising awareness about kidney health and the impact of kidney diseases on individual well-being. Since its inception in 2006, it has evolved into a significant global health movement, spotlighting the substantial global health impact of kidney disease, a leading Read more
Clinical Research Focus 26th edition | Cromos Pharma
Clinical Research Focus. 26th Edition Navigating the Future of Gene Therapy In January 2024, the FDA issued a guidance document, outlining critical considerations in the clinical development of CRISPR/CAS9 drug candidates. This guidance addresses the nuanced challenges associated with the development of human gene-edited (GE) products, placing particular emphasis on mitigating risks linked to both the gene therapy product itself Read more
Celebrating Rare Disease Day 2024 | Cromos Pharma
Celebrating Rare Disease Day 2024 Today, on Rare Disease Day, we emphasize the importance of bringing attention to conditions that, though rare, affect millions around the world. A striking total of over 440 million people globally face these diseases, underlining the critical need for increased advocacy and decisive action. Currently, the world benefits from the availability of over 500 drugs Read more

Schedule a meeting

We are excited to connect with you, understand your goals, and explore how we can support your needs.

Contact us